‘Molecular glue degrader’ reaches cancer trial following ICR research programme 23 Feb 2023 The biotechnology company Monte Rosa Therapeutics – originally a spin-out from research at The Institute of Cancer Research, London – has announced that the first patient has received their ‘molecular glue degrader’ drug as part of a clinical trial in oncology. Find out more Show/Hide
Monte Rosa Therapeutics lists on New York Stock Exchange 10 Sep 2021 Monte Rosa Therapeutics, a biotechnology company originally formed as a spinout from science at The Institute of Cancer Research, London, partly funded by Cancer Research UK, is now listed on the Nasdaq stock exchange in New York. Find out more Show/Hide
ICR and Cancer Research UK spinout company Monte Rosa Therapeutics raises USD96m in ‘Series B’ Financing 24 Sep 2020 Monte Rosa Therapeutics, a company originally formed as a spinout from Cancer Research UK-funded drug discovery research at the ICR, in collaboration with Versant’s drug discovery engine Ridgeline Therapeutics, has closed a $96m ‘series B’ financing from investors to support the further development of its drug pipeline. Find out more Show/Hide
ICR and Cancer Research UK spinout company Monte Rosa Therapeutics launches with library of anti-cancer compounds 10 Jun 2020